IL-23 inhibition in scalp psoriasis: what’s new?

Involvement of the scalp is common in psoriasis patients and can induce considerable distress with sometimes significant effects on quality of life. In addition to new study findings on the three established interleukin (IL)-23p19 inhibitors guselkumab, tildrakizumab and risankizumab, new post-hoc analyses of phase III data on picankibart were also presented at this year’s EADV Annual Meeting.